Utilization, reliability, and clinical impact of point-of-care testing during critical care transport: six years of experience.

The application of VAP-II may be useful not only in elucidating the roles played by specific lipoprotein abnormalities in contributing to CHD, but also in yielding valuable insight into the specific benefits of therapeutic regimens to decrease CHD risk. Evidence for an independent relationship between insulin resistance and fasting plasma HDL-cholesterol, triglyceride and insulin concentrations. The ratio of waist-to-hip circumference, plasma insulin level, and glucose intolerance as independent predictors of the HDL2 cholesterol level in older adults. N Engl Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. et al. Relation of serum total cholesterol and high-density lipoprotein cholesterol percentage to the incidence of definite coronary events: twenty-year follow-up of the Donolo-Tel Aviv Prospective Coronary Artery Disease Study. Angiographic evidence for the role of triglyceride-rich lipopro-teins in progression of coronary artery disease. Eur Heart J 1998;19:H31– 6. 9. Krauss RM. Relationship of intermediate and low-density lipoprotein sub-species to risk of coronary artery disease. plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. between hyperinsulinemia and remnant lipoprotein concentrations in patients with impaired glucose tolerance. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. several surrogate estimates of insulin resistance and quantification of insulin-mediated glucose disposal in 490 healthy nondiabetic volunteers. The use of point-of-care testing (POCT) has been reported in the setting of critical care transport (1– 6), although the overall benefits have not been evaluated in depth. In addition, problems with testing reliability may be uncovered only after an extended period of field use. This report describes the use of POCT by our critical care transport program over 6 years. All critical care transports made from January 1996 to December 2001 were reviewed. Transport vehicles were ambulances or twin-engine jets. The transport teams consisted of a physician on transport or with radio contact, a respiratory therapist, and a registered nurse. All transports were equipped with i-STAT ® portable analyzers (i-STAT ® Corporation) and disposable cartridges for testing. The analyzer and cartridges were stored in an insulated bag for temperature control during the trip. The analytical performance verification protocol (electronic controls) recommended in the i-STAT System Manual was followed before each patient test. Liquid controls were run monthly. Proficiency testing was completed in accordance with the requirements of the College of Amer-ican Pathologists.crit, …